What disease-modifying medication should be prescribed for a patient with rheumatoid arthritis?

Disease-Modifying Medication for Rheumatoid Arthritis

Start methotrexate 15–25 mg weekly with folic acid supplementation immediately upon diagnosis, rapidly escalating to 25–30 mg weekly within a few weeks, and add low-dose prednisone ≤10 mg daily for less than 3 months as a bridge to rapid symptom control. 1, 2

Rationale for Methotrexate as First-Line Therapy

• Methotrexate is the anchor DMARD for all patients with active rheumatoid arthritis and must be initiated as soon as the diagnosis is confirmed, because delays lead to irreversible joint damage. 1, 2
• The optimal therapeutic dose is 25–30 mg weekly (approximately 0.3 mg/kg in Western populations, 16 mg in Japan due to lower body weight), achieved through rapid dose escalation within 4–6 weeks. 1, 2
• If oral methotrexate at 20–25 mg weekly is not tolerated or ineffective after 3 months, switch to subcutaneous administration before declaring treatment failure, as subcutaneous formulation offers higher bioavailability and fewer gastrointestinal side effects. 1, 2, 3
• When methotrexate is contraindicated (e.g., severe liver disease, significant renal impairment), leflunomide or sulfasalazine should be used as first-line alternatives. 1, 4

Glucocorticoid Bridge Strategy

• Add low-dose oral prednisone ≤10 mg daily (or equivalent) at diagnosis for rapid symptom control while methotrexate takes effect, using the lowest effective dose for the shortest duration (generally <3 months). 1, 2
• Taper and discontinue prednisone as soon as disease control is achieved with DMARD optimization; prolonged use beyond 1–2 years markedly increases risks of osteoporosis, fractures, cataracts, and cardiovascular disease. 1, 2, 5
• High-dose corticosteroids as sole therapy do not halt radiographic progression despite providing symptom relief and are therefore inappropriate. 2

Treatment Targets and Monitoring Schedule

• Primary target: ACR/EULAR remission (SDAI ≤3.3, CDAI ≤2.8, or Boolean criteria: ≤1 tender joint, ≤1 swollen joint, CRP ≤1 mg/dL, patient global ≤1 on 0–10 scale). 1, 2
• Acceptable alternative: low disease activity (SDAI ≤11 or CDAI ≤10), particularly in patients with long-standing disease or when remission is unattainable. 1, 2
• Assess disease activity every 1–3 months during active disease using composite measures (joint counts, patient/physician global assessments, ESR or CRP). 1, 2
• Expect ≥50% improvement within the first 3 months of therapy; failure to achieve this threshold mandates immediate treatment escalation. 1, 2
• The treatment target must be reached within 6 months; if not, therapy must be escalated or modified. 1, 2

Escalation Strategy for Inadequate Response

Patients Without Poor Prognostic Factors

• Add combination conventional synthetic DMARDs (triple therapy: methotrexate + sulfasalazine 500 mg twice daily titrated to 1000 mg twice daily + hydroxychloroquine 400 mg daily) when immediate biologic therapy is not indicated. 1, 2, 4
• Triple-DMARD therapy yields sustained improvement rates of approximately 77% versus 33% with methotrexate alone in patients with moderate disease activity. 2

Patients With Poor Prognostic Factors

• Poor prognostic factors include: high rheumatoid factor or anti-CCP titers, high baseline disease activity (DAS28 >5.1), early erosive changes, or failure of two conventional synthetic DMARDs. 1, 2
• Add a biologic DMARD or JAK inhibitor to methotrexate when inadequate response persists after 3–6 months of optimized conventional DMARD therapy. 1, 2
• First-line biologic agents: TNF-α inhibitors (adalimumab, etanercept, infliximab, certolizumab pegol, golimumab) combined with methotrexate whenever possible, as combination therapy demonstrates superior efficacy compared with biologic monotherapy. 1, 2
• Alternative biologic classes: IL-6 receptor antagonists (tocilizumab, sarilumab), T-cell costimulation modulators (abatacept), or rituximab (particularly for seropositive patients or those with prior lymphoproliferative disorders). 1, 2
• JAK inhibitors (tofacitinib, baricitinib, upadacitinib, filgotinib) are appropriate when biologics are unsuitable or after biologic failure, though careful consideration of risks of major cardiovascular events, malignancies, and thromboembolic events is required. 1, 6

Management After First Biologic Failure

• Switch to a biologic with a different mechanism of action rather than a second agent from the same class; registry and observational data show superior efficacy with a mechanism-switch. 1, 2
• After failure of a first TNF inhibitor, either another TNF inhibitor or a biologic from a different class may be used, but a mechanism-switch is now preferred. 1, 6
• Allow 3–6 months to fully assess the efficacy of any newly introduced biologic or targeted synthetic DMARD before making further therapeutic changes. 1, 2

De-Escalation in Sustained Remission

• When sustained remission is maintained for ≥1 year, cautious tapering of therapy can be considered, beginning with prednisone discontinuation followed by gradual reduction of DMARD dose. 1, 2, 4
• Approximately 15–25% of patients may achieve sustained drug-free remission, particularly those with shorter symptom duration, absence of autoantibodies, lower disease activity before remission, and less baseline disability. 2, 4
• DMARDs may be tapered in sustained remission but should not be stopped completely in most patients. 6

Critical Pitfalls to Avoid

• Delaying DMARD initiation permits unchecked irreversible joint damage and poorer functional prognosis; treatment must commence at diagnosis. 1, 2
• Relying on NSAIDs or corticosteroids as sole therapy provides only symptomatic relief without disease modification and fails to prevent radiographic joint damage. 2
• Undertreating with suboptimal methotrexate doses (<20–25 mg weekly) prevents achieving treatment targets; ensure maximal tolerated dose for at least 3 months before declaring failure. 1, 2, 4
• Not escalating therapy when <50% improvement at 3 months or target not reached at 6 months; ongoing joint damage can become irreversible even with modest disease activity. 1, 2
• Continuing systemic corticosteroids beyond 1–2 years; cumulative adverse effects (fractures, cataracts, cardiovascular disease, osteoporosis) outweigh symptomatic benefits. 1, 2